Physician profile
Amy Orgeron
NPI 1508218561
$6,078.84
in general payments reported to CMS, 2019-2025
26 companies · $275 in 2025
The $275 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,478 · 2022: $1,149 · 2023: $865 · 2024: $2,312 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,679 · Travel and Lodging: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,678.71 |
| Travel and Lodging | $773.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,915.43 | 2021-2025 | Wavewriter Alpha Prime 16, Intracept, Intracept Rf Probe |
| Nevro Corp. | $711.19 | 2021-2024 | Senza |
| Abbott Laboratories | $367.33 | 2021-2024 | Proclaim, Eterna |
| Genzyme Corporation | $365.59 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $249.99 | 2022-2024 | Austedo Xr |
| Dexcom, INC. | $238.75 | 2021-2023 | Dexcom G7 Gss (161) |
| Medtronic, INC. | $183.92 | 2021-2022 | |
| Abbvie INC. | $170.20 | 2022-2024 | |
| Globus Medical, INC. | $149.96 | 2025 | Senza, Vyrsa V1, Omnia |
| Averitas Pharma INC. | $146.28 | 2024 | Qutenza |
| Nalu Medical, INC. | $144.15 | 2021-2024 | Nalu Neurostimulation System |
| Grt US Holding, INC. | $140.27 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $129.10 | 2022 | |
| Amgen INC. | $124.99 | 2022 | |
| Dermavant Sciences, INC. | $124.99 | 2023 | Vtama |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $124.07 | 2024 | Wegovy |
| Viiv Healthcare Company | $121.49 | 2021 | |
| Axsome Therapeutics, INC. | $121.34 | 2023 | Auvelity |
| Relievant Medsystems, INC. | $117.86 | 2021 | |
| Agile Therapeutics, INC. | $111.36 | 2021 | |
| Neurocrine Biosciences, INC. | $94.11 | 2021 | |
| Neurelis, INC. | $82.37 | 2021 | |
| Spr Therapeutics, INC | $66.12 | 2024 | Sprint Pns System |
| Hydrofera LLC | $41.63 | 2025 | Hydrofera Blue |
| Convatec INC. | $21.79 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $14.56 | 2024 | Exparel, Zilretta, Iovera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Orgeron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.